Perseus Proteomics Inc.
Explanation Regarding Fundraising
Fundraising is planned using stock acquisition rights. The allottee is Macquarie Bank Limited. The number of potential shares is 4,600,000 shares, representing 24.96% of issued shares. The expected proceeds are approximately 4,595 million yen, and the exercise period is from 2026-12-09 to 2028-12-08. Main uses of proceeds are research and development expenses and working capital, with planned application timing around June 2027. Past allocations of the 29th stock acquisition rights are also listed.
Key Figures
- Potential shares from stock acquisition rights: 4,600,000 shares
- Percentage of potential shares: 24.96%
- Issue price: Total 1,334,000 yen (29 yen per stock acquisition right)
AI要約
Overview of Fundraising
Perseus Proteomics Inc. has announced fundraising through the 31st series of stock acquisition rights, with the allottee being Macquarie Bank Limited. The potential shares total 4,600,000 shares, representing 24.96% of the total issued shares. Expected proceeds are approximately 459,534,000 yen, and the exercise period is two years from 2026/12/09 to 2028/12/08. There is a floor for the initial exercise price of 56 yen, and a clause that adjusts the exercise price to 92% of the closing price. The purpose is to allocate funds to research and development and working capital.
Use of Proceeds and Schedule
Proceeds are planned to be allocated to research and development related to drug discovery and antibodies, working capital, and new development areas such as AI-driven drug discovery. Some funds are planned to be applied by June 2027, with final allocation expected between June 2027 and March 2029. For the 29th series of stock acquisition rights, 705 million yen has already been allocated.
Perseus Proteomics Inc.
Company overview · Stock price · Financial data · All IR